SAN

77.32

+1.3%↑

ARGX

712

+2.51%↑

SHL.DE

35.08

+1.24%↑

FRE

37.09

-1.96%↓

PHIA

22.96

-0.95%↓

SAN

77.32

+1.3%↑

ARGX

712

+2.51%↑

SHL.DE

35.08

+1.24%↑

FRE

37.09

-1.96%↓

PHIA

22.96

-0.95%↓

SAN

77.32

+1.3%↑

ARGX

712

+2.51%↑

SHL.DE

35.08

+1.24%↑

FRE

37.09

-1.96%↓

PHIA

22.96

-0.95%↓

SAN

77.32

+1.3%↑

ARGX

712

+2.51%↑

SHL.DE

35.08

+1.24%↑

FRE

37.09

-1.96%↓

PHIA

22.96

-0.95%↓

SAN

77.32

+1.3%↑

ARGX

712

+2.51%↑

SHL.DE

35.08

+1.24%↑

FRE

37.09

-1.96%↓

PHIA

22.96

-0.95%↓

Home・Lista de Ações・Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi SA

Abrir

SetorSaúde

60.55 0.33

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

60.3

Máximo

61.05

Indicadores-chave
By Trading Economics
Rendimento	-33M 9.5M
Vendas	-66M 152M
P/E Médio do Setor	25.593 50.102
EPS	0.185
Margem de lucro	6.216
Funcionários	1,950
EBITDA	-45M 18M

Recomendações
By TipRanks
Recomendações	Comprar
Previsão para 12 meses	+22.46% upside

Dividendos
By Dow Jones
Próximos Ganhos	23 de jul. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	-972M 3.1B
Abertura anterior	60.22
Fecho anterior	60.55

Sentimento de Notícias

By Acuity

50%

154 / 344 Ranking em Healthcare

Laboratorios Farmaceuticos Rovi SA Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

26 de mai. de 2026, 16:52 UTC

Notícias Principais

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q Rev $1.76B >SQM

26 de mai. de 2026, 23:57 UTC

Ganhos

Sociedad Quimica 1Q EPS $1.28 >SQM

26 de mai. de 2026, 23:48 UTC

Conversa de Mercado

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q EPS $11.61 >WEBC

26 de mai. de 2026, 21:54 UTC

Ganhos

Webco Industries 3Q Sales $179.6M >WEBC

26 de mai. de 2026, 21:48 UTC

Conversa de Mercado

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 de mai. de 2026, 21:00 UTC

Conversa de Mercado

ESG Roundup: Market Talk

26 de mai. de 2026, 20:58 UTC

Aquisições, Fusões, Aquisições de Empresas

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 19:22 UTC

Conversa de Mercado

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 de mai. de 2026, 19:17 UTC

Conversa de Mercado

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 de mai. de 2026, 18:56 UTC

Conversa de Mercado

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 de mai. de 2026, 18:03 UTC

Conversa de Mercado

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 de mai. de 2026, 17:42 UTC

Conversa de Mercado

Grains Await Fresh Trading Catalyst -- Market Talk

26 de mai. de 2026, 17:33 UTC

Conversa de Mercado

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 de mai. de 2026, 17:21 UTC

Conversa de Mercado

Canada Faces a Labor Market Squeeze -- Market Talk

26 de mai. de 2026, 16:52 UTC

Conversa de Mercado

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 de mai. de 2026, 16:43 UTC

Conversa de Mercado

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 de mai. de 2026, 16:24 UTC

Conversa de Mercado

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 de mai. de 2026, 16:21 UTC

Conversa de Mercado

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Energy & Utilities Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Financial Services Roundup: Market Talk

26 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Aquisições, Fusões, Aquisições de Empresas

Auto & Transport Roundup: Market Talk

26 de mai. de 2026, 16:16 UTC

Conversa de Mercado

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 de mai. de 2026, 16:01 UTC

Conversa de Mercado

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 de mai. de 2026, 15:21 UTC

Conversa de Mercado

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparação entre Pares

Variação de preço

Laboratorios Farmaceuticos Rovi SA Previsão

Preço-alvo

By TipRanks

22.46% parte superior

Previsão para 12 meses

Média 73.6 EUR 22.46%

Máximo 83 EUR

Mínimo 64.2 EUR

Com base em 2 analistas de Wall Street que oferecem metas de preço de 12 meses para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

2 ratings

Comprar

Manter

Vender

Com base em 2 analistas que deram avaliações de ações para Laboratorios Farmaceuticos Rovi SA - Dist nos últimos 3 meses.

Sentimento

By Acuity

154 / 344 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre Laboratorios Farmaceuticos Rovi SA

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.